on-invasive detection of brain tumour genetic mutations using specialised MRI scans of brain biochemistry in clinical practice
Not Applicable
- Conditions
- Patients with radiological appearances consistent with diffuse glioma or tissue-proven diffuse gliomaCancer
- Registration Number
- ISRCTN18300486
- Lead Sponsor
- niversity of Edinburgh
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ongoing
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
1. Radiological appearances consistent with diffuse glioma or tissue proven diffuse glioma
2. A signed and dated, informed consent must be obtained prior to study participation
3. Adults aged 18 - 75 years
4. WHO performance status 0 – 1
5. Measurable disease in the case of post-surgery subjects
Exclusion Criteria
1. Participants for whom MRI is contraindicated
2. Patients with tumours in locations that preclude tissue sampling by biopsy or surgical resection.
3. Patients whose co-morbidities or functional status precludes tissue acquisition by biopsy or surgical resection.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 2 hydroxyglutarate concentration determined using in vivo MR spectroscopy at the time of MRI examination
- Secondary Outcome Measures
Name Time Method IDH mutation status as determined by immunohistochemistry and gene sequencing from tissue samples collected at the time of surgery